Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.

König L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, Kimmig R, Horn PA, Rebmann V.

Oncoimmunology. 2017 Sep 27;7(1):e1376153. doi: 10.1080/2162402X.2017.1376153. eCollection 2017.

PMID:
29296534
2.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y.

Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

PMID:
29232552
3.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

4.

Fast and reproducible iSERS microscopy of single HER2-positive breast cancer cells using gold nanostars as SERS nanotags.

Wang XP, Walkenfort B, König M, König L, Kasimir-Bauer S, Schlücker S.

Faraday Discuss. 2017 Dec 4;205:377-386. doi: 10.1039/c7fd00135e.

PMID:
28902197
5.

Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer.

Bredemeier M, Edimiris P, Mach P, Kubista M, Sjöback R, Rohlova E, Kolostova K, Hauch S, Aktas B, Tewes M, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2017 Oct;63(10):1585-1593. doi: 10.1373/clinchem.2016.269605. Epub 2017 Aug 3.

PMID:
28778937
6.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.

Giannopoulou L, Kasimir-Bauer S, Lianidou ES.

Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Review.

7.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Anticancer Res. 2017 Jun;37(6):3117-3128.

PMID:
28551653
8.

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.

Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, Kimmig R, Kuhlmann JD.

Oncotarget. 2017 Jul 25;8(30):48820-48831. doi: 10.18632/oncotarget.16179.

9.

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.

Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2017 Apr 11;8(15):24303-24313. doi: 10.18632/oncotarget.13286.

10.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

11.

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Oncotarget. 2017 Mar 28;8(13):21429-21443. doi: 10.18632/oncotarget.15249.

12.

Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.

Buderath P, Kasimir-Bauer S, Aktas B, Rasch J, Kimmig R, Zeller T, Heubner M.

Future Sci OA. 2016 Oct 12;2(4):FSO145. doi: 10.4155/fsoa-2016-0040. eCollection 2016 Dec.

13.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.

Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group.

BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.

14.

iSERS microscopy guided by wide field immunofluorescence: analysis of HER2 expression on normal and breast cancer FFPE tissue sections.

Wang XP, Zhang Y, König M, Papadopoulou E, Walkenfort B, Kasimir-Bauer S, Bankfalvi A, Schlücker S.

Analyst. 2016 Aug 15;141(17):5113-9. doi: 10.1039/c6an00927a.

PMID:
27302205
15.

Serum concentrations of soluble B7-H4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes.

Mach P, Köninger A, Wicherek L, Kimmig R, Kasimir-Bauer S, Birdir C, Schmidt B, Gellhaus A.

Am J Reprod Immunol. 2016 Aug;76(2):149-54. doi: 10.1111/aji.12527. Epub 2016 Jun 15.

PMID:
27302185
16.

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.

Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 Jul 5;7(27):41677-41690. doi: 10.18632/oncotarget.9528.

17.

Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?

Kasimir-Bauer S, Reiter K, Aktas B, Bittner AK, Weber S, Keller T, Kimmig R, Hoffmann O.

Sci Rep. 2016 May 23;6:26355. doi: 10.1038/srep26355.

18.

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?

Chebouti I, Blassl C, Wimberger P, Neubauer H, Fehm T, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 May 3;7(18):26454-64. doi: 10.18632/oncotarget.8524.

19.

Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies.

Kuessel L, Kasimir-Bauer S, Zeillinger R, Pateisky P, Ott J, Zeisler H, Birdir C.

Hypertens Pregnancy. 2016 Aug;35(3):323-9. doi: 10.3109/10641955.2016.1143487. Epub 2016 Mar 1.

PMID:
26930176
20.

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.

Kasimir-Bauer S, Bittner AK, König L, Reiter K, Keller T, Kimmig R, Hoffmann O.

Breast Cancer Res. 2016 Feb 12;18(1):20. doi: 10.1186/s13058-016-0679-3.

21.

The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.

König L, Kasimir-Bauer S, Hoffmann O, Bittner AK, Wagner B, Manvailer LF, Schramm S, Bankfalvi A, Giebel B, Kimmig R, Horn PA, Rebmann V.

Hum Immunol. 2016 Sep;77(9):791-9. doi: 10.1016/j.humimm.2016.01.002. Epub 2016 Jan 12.

PMID:
26796737
22.

Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.

Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, Kimmig R, Siffert W.

Arch Gynecol Obstet. 2015 Dec;292(6):1367-72. doi: 10.1007/s00404-015-3802-2. Epub 2015 Jun 27.

PMID:
26115884
23.

Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.

Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, Kimmig R, Heubner M.

Arch Gynecol Obstet. 2015 Nov;292(5):1117-25. doi: 10.1007/s00404-015-3748-4. Epub 2015 May 19.

PMID:
25986892
24.

Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia.

Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, Kimmig R, Köninger A.

Arch Gynecol Obstet. 2015 Nov;292(5):1033-42. doi: 10.1007/s00404-015-3745-7. Epub 2015 May 15.

PMID:
25975456
25.

Changes in the Blood Serum Levels of the Costimulatory Soluble B7-H4 Molecule in Pregnant Women During the Peripartal Phase.

Mach P, Gellhaus A, Wicherek L, Schmidt B, Kimmig R, Kasimir-Bauer S, Köninger A.

Am J Reprod Immunol. 2015 Sep;74(3):209-15. doi: 10.1111/aji.12392. Epub 2015 Apr 24.

PMID:
25907449
26.

Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients.

Köninger A, Koch L, Enekwe A, Birdir C, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Gynecol Endocrinol. 2015 Jan;31(1):26-30. doi: 10.3109/09513590.2014.959436. Epub 2014 Sep 15.

PMID:
25222840
27.

Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis.

Köninger A, Koch L, Edimiris P, Nießen S, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:124-9. doi: 10.1016/j.ejogrb.2014.07.029. Epub 2014 Aug 4.

PMID:
25150949
28.

Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.

Tewes M, Kasimir-Bauer S, Welt A, Schuler M, Kimmig R, Aktas B.

J Cancer Res Clin Oncol. 2015 Jan;141(1):87-92. doi: 10.1007/s00432-014-1784-2. Epub 2014 Aug 10.

PMID:
25108406
29.

ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.

Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2014 Oct;60(10):1282-9. doi: 10.1373/clinchem.2014.224808. Epub 2014 Jul 11.

30.

Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.

Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Arch Gynecol Obstet. 2014 Nov;290(5):1023-30. doi: 10.1007/s00404-014-3317-2. Epub 2014 Jun 25.

PMID:
24961320
31.

Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome.

Köninger A, Edimiris P, Koch L, Enekwe A, Lamina C, Kasimir-Bauer S, Kimmig R, Dieplinger H.

Endocr Connect. 2014 Sep;3(3):120-6. doi: 10.1530/EC-14-0053. Epub 2014 Jun 13.

32.

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.

Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, Kimmig R, Süleyman E, Kuhlmann JD.

Gynecol Oncol. 2014 Jun;133(3):467-72. doi: 10.1016/j.ygyno.2014.03.574. Epub 2014 Apr 5.

PMID:
24713547
33.
34.

Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.

Köninger A, Sauter L, Edimiris P, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.

Hum Reprod. 2014 Mar;29(3):518-24. doi: 10.1093/humrep/det468. Epub 2014 Jan 12.

PMID:
24419495
35.

Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.

Kuhlmann JD, Baraniskin A, Hahn SA, Mosel F, Bredemeier M, Wimberger P, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2014 Jan;60(1):206-13. doi: 10.1373/clinchem.2013.213066. Epub 2013 Nov 8.

36.

Anti-Mullerian-hormone levels during pregnancy and postpartum.

Köninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, Kimmig R, Birdir C.

Reprod Biol Endocrinol. 2013 Jul 11;11:60. doi: 10.1186/1477-7827-11-60.

37.

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.

Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S.

Int J Gynecol Cancer. 2013 Jun;23(5):839-45. doi: 10.1097/IGC.0b013e3182907109.

PMID:
23694981
38.

Circulating tumor cells in breast cancer.

Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, Hartkopf A, Fehm T.

Clin Chim Acta. 2013 Aug 23;423:39-45. doi: 10.1016/j.cca.2013.03.029. Epub 2013 Apr 24. Review.

PMID:
23623805
39.

Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.

Aktas B, Kasimir-Bauer S, Lehmann N, Kimmig R, Tewes M.

Oncol Rep. 2013 Jul;30(1):441-7. doi: 10.3892/or.2013.2409. Epub 2013 Apr 22.

PMID:
23604361
40.

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.

Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES.

Breast Cancer Res. 2013 Mar 7;15(2):R20. doi: 10.1186/bcr3395.

41.

Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.

Aktas B, Kasimir-Bauer S, Wimberger P, Kimmig R, Heubner M.

Anticancer Res. 2013 Jan;33(1):329-36.

PMID:
23267165
42.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group.

Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243.

43.

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.

Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S.

BMC Cancer. 2012 Jul 31;12:325. doi: 10.1186/1471-2407-12-325.

44.

microRNA and the pathogenesis of ovarian cancer--a new horizon for molecular diagnostics and treatment?

Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S.

Clin Chem Lab Med. 2012 Jan 13;50(4):601-15. doi: 10.1515/cclm-2011-0847. Review.

PMID:
22505556
45.

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.

Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T.

Breast Cancer Res. 2012 Jan 20;14(1):R15.

46.

Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.

Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, Kimmig R, Kasimir-Bauer S.

Anticancer Res. 2011 Oct;31(10):3623-8.

PMID:
21965788
47.

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T; DETECT study group.

Breast Cancer Res. 2011 Jul 11;13(4):R71. doi: 10.1186/bcr2916.

48.

Circulating 20S proteasome in patients with non-metastasized breast cancer.

Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU.

Anticancer Res. 2011 Jun;31(6):2197-201.

PMID:
21737641
49.

Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.

Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P.

Int J Gynecol Cancer. 2011 Jul;21(5):822-30. doi: 10.1097/IGC.0b013e318216cb91.

PMID:
21613958
50.

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.

Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, Rack B, Schneeweiss A, Fehm T.

Gynecol Oncol. 2011 Aug;122(2):356-60. doi: 10.1016/j.ygyno.2011.04.039. Epub 2011 May 24.

PMID:
21605893

Supplemental Content

Loading ...
Support Center